Published in Transfusion on February 27, 2009
An overview of occult hepatitis B virus infection. World J Gastroenterol (2011) 1.32
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. Transfus Med Rev (2011) 1.11
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
The challenges of meeting the blood transfusion requirements in Sub-Saharan Africa: the need for the development of alternatives to allogenic blood. J Blood Med (2011) 0.98
Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission risk. Transfusion (2013) 0.95
Quarantine Plasma: Quo vadis? Transfus Med Hemother (2010) 0.87
Validation of Virus NAT for HIV, HCV, HBV and HAV Using Post-Mortal Blood Samples. Transfus Med Hemother (2012) 0.86
Characterisation of hepatitis C virus genotype among blood donors at the regional blood transfusion centre of Ouagadougou, Burkina Faso. Blood Transfus (2014) 0.83
Pre- and post-transfusion testing for hepatitis B virus surface antigen and antibody in blood recipients: a single-institution experience in an area of high endemicity. Ann Lab Med (2011) 0.83
Reducing the risk of hepatitis B virus transfusion-transmitted infection. J Blood Med (2011) 0.82
Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infection. Blood Transfus (2013) 0.82
Occult hepatitis B virus infection and blood transfusion. World J Hepatol (2015) 0.81
Criteria for hepatitis B virus screening and validation of blood components in Italy: the position of the SIMTI HBV working group. Blood Transfus (2011) 0.81
Highly sensitive detection of hepatitis B virus surface antigen by use of a semiautomated immune complex transfer chemiluminescence enzyme immunoassay. J Clin Microbiol (2013) 0.79
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int (2016) 0.79
Molecular virology in transfusion medicine laboratory. Blood Transfus (2012) 0.79
Investments in blood safety improve the availability of blood to underserved areas in a sub-Saharan African country. ISBT Sci Ser (2014) 0.79
A pilot study on screening blood donors with individual-donation nucleic acid testing in China. Blood Transfus (2013) 0.79
Occult hepatitis B virus infection among blood donors from the Brazilian Amazon: implications for transfusion policy. Vox Sang (2014) 0.78
The impact of HIV-associated anaemia on the incidence of red blood cell transfusion: implications for blood services in HIV-endemic countries. Transfus Apher Sci (2014) 0.77
Comment on: One window-period donation in two years of individual donor-nucleic acid test screening for hepatitis B, hepatitis C and human immunodeficiency virus. Rev Bras Hematol Hemoter (2013) 0.75
Motivators and deterrents to blood donation among Black South Africans: a qualitative analysis of focus group data. Transfus Med (2015) 0.75
Namibia's transition from whole blood-derived pooled platelets to single-donor apheresis platelet collections. Transfusion (2015) 0.75
Molecular diagnosis of the human immunodeficiency, Hepatitis B and C viruses among blood donors in Lomé (Togo) by multiplex real time PCR. Pan Afr Med J (2016) 0.75
Screening and diagnosis of HBV in low-income and middle-income countries. Nat Rev Gastroenterol Hepatol (2016) 0.75
Prevalence of p24 antigen among a cohort of HIV antibody negative blood donors in Sokoto, North Western Nigeria--the question of safety of blood transfusion in Nigeria. Pan Afr Med J (2014) 0.75
Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion (2009) 2.00
Cancer in the Republic of the Marshall Islands. Pac Health Dialog (2004) 1.60
Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion (2013) 1.43
Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA. J Clin Microbiol (2006) 1.38
Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol (2008) 1.30
Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion (2010) 1.29
Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol (2008) 1.25
Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections. Transfusion (2013) 1.12
Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion (2011) 1.10
Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang (2006) 1.00
Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain. Transfusion (2009) 1.00
Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus Type 1 in blood donors. Transfusion (2013) 0.99
Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology (2009) 0.99
Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission risk. Transfusion (2013) 0.95
Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay. Transfusion (2013) 0.95
Characteristics of Marshallese with Type 2 Diabetes on Oahu: A Pilot Study to Implement a Community-Based Diabetic Health Improvement Project. Calif J Health Promot (2005) 0.95
Nucleic acid testing (NAT) in high prevalence-low resource settings. Biologicals (2010) 0.93
Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion (2009) 0.92
Efficacy of individual nucleic acid amplification testing in reducing the risk of transfusion-transmitted hepatitis B virus infection in Switzerland, a low-endemic region. Transfusion (2010) 0.84
Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios. Transfusion (2013) 0.82
A retrospective study of 75 cases of splenic abscess. Indian J Surg (2011) 0.82
Role of regulatory agencies. Biologicals (2009) 0.81
Calibration of HIV-1 working reagents for nucleic acid amplification techniques against the 1st international standard for HIV-1 RNA. J Virol Methods (2003) 0.80
Risk assessment and cost-effectiveness/utility analysis. Biologicals (2009) 0.80
Efficacy of POSSUM score in predicting the outcome in patients undergoing emergency laparotomy. Pol Przegl Chir (2014) 0.76
Resident-driven group medical visits for diabetes mellitus in an ethnically diverse clinic population. Hawaii Med J (2010) 0.76
A mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections. Transfusion (2014) 0.76
Performance of two triplex nucleic acid test systems. Transfusion (2010) 0.75
Estimates of prevalence of anti-SARS-CoV-2 antibodies among blood donors in eight provinces of South Africa in November 2021. Res Sq (2022) 0.75
Use of Blood Donor Screening to Monitor Prevalence of HIV and Hepatitis B and C Viruses, South Africa. Emerg Infect Dis (2017) 0.75
Design of a dual-hormone model predictive control for artificial pancreas with exercise model. Conf Proc IEEE Eng Med Biol Soc (2016) 0.75